The goal of the clinical development program for a proposed
biosimilar is to use the data from the pivotal trials to demonstrate that there
is no clinically meaningful difference between the proposed biosimilar and the
reference product in terms of
efficacy, safety, and immunogenicity.1
Once approved for use, it is important to continue to monitor
the safety of the new biosimilar product.